Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort studyMarie Kostine, Thierry Schaeverbeke, L. Rouxel et al.|Annals of the Rheumatic Diseases|2017Cited by 302
Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligoM. Larsabal, Julien Sénéschal, A. Marti et al.|Journal of the American Academy of Dermatology|2017Cited by 157
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse eventsMarie Kostine, Thierry Schaeverbeke, Julien Sénéschal et al.|European Journal of Cancer|2021Cited by 93
Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 TherapyL. Dousset, Lise Boussemart, F. Poizeau et al.|JCO Precision Oncology|2021Cited by 61
Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanomaMarine Rousset, Mathiéu Molimard, Caroline Dutriaux et al.|Clinica Chimica Acta|2017Cited by 36